# HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

> **NCT05883748** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Disc Medicine, Inc** · enrollment: 230 (estimated)

## Conditions studied

- Erythropoietic Protoporphyria

## Interventions

- **DRUG:** DISC-1459
- **DRUG:** DISC-1459

## Key facts

- **NCT ID:** NCT05883748
- **Lead sponsor:** Disc Medicine, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-08-31
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05883748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05883748, "HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05883748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*